Two mid‑stage readouts in atopic dermatitis moved markets: Evommune reported EVO301 achieved its phase IIa primary endpoint with competitive EASI reductions, sending shares sharply higher, while Nektar’s long‑acting rezpegaldesleukin maintained and deepened skin‑clearance responses at one year when switched to maintenance dosing. Evommune plans a phase IIb subcutaneous program to optimize dosing; Nektar is preparing a Phase III design that allows responders to transition to maintenance regimens. Both programs position new mechanisms — IL‑18 inhibition and IL‑2 modulation — as potential challengers to incumbent biologics such as Sanofi/Regeneron’s Dupixent.